Organizers:
David H. Henry, MD – University of Pennsylvania
Ellen Napier, CRNP – University of Pennsylvania
Stephen J. Schuster, MD – University of Pennsylvania
Program Purpose
Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:
- The rationale for common approaches to immunotherapy
- The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
- Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
- The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through two Immuno-Oncology (IO) Cup o' Joe webinars after the program, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. Breakfast and lunch will be served at the live portion of this event.
For more information, including program objectives, click here.
This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).
Advanced registration for this program closed on July 28, 2017 at 5 p.m. ET.
SITC members are eligible for discounted registration rates. To receive discounted member rates, your membership dues must be current through 2017.
Click here to learn more about the registration rates for members and non-members.
Program Agenda
Preprogram Course: Introduction to Immunology
Participation in this online preprogram course is strongly recommended as it contains information that will not be covered at the program on August 4. This interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Please click HERE to access the course.
August 4 Program
5.5 AMA PRA Category 1 Credits™ Click here for more detailed CME, CNE and CPE information and program objectives.
Presentations include time for Audience Response System (ARS)-assisted audience
interaction as well as general question and answer time.
7 – 8 a.m.
|
Check-in, Onsite Registration and Networking
|
Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice
|
Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy
|
8 – 8:05 a.m.
|
Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer
|
8:05 – 8:35 a.m.
|
Basic Principles of Cancer Immunotherapy David H. Henry, MD – University of Pennsylvania
|
8:35 – 8:55 a.m.
|
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD – Thomas Jefferson University Hospital
|
8:55 – 9:15 a.m.
|
Immunotherapy for the Treatment of Lung Cancer Corey J. Langer, MD – University of Pennsylvania
|
9:15 – 9:35 a.m.
|
Immunotherapy for the Treatment of Genitourinary Cancers Vivek Narayan, MD MSCE – University of Pennsylvania
|
9:35 – 9:55 a.m
|
Immunotherapy for the Treatment of Hematologic Malignancies Stephen J. Schuster, MD – University of Pennsylvania
|
9:55 – 10:15 a.m
|
Immunotherapy for the Treatment of Head and Neck Cancers Joshua Bauml, MD – University of Pennsylvania
|
10:15 – 10:25 a.m
|
Break
|
Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice
|
10:25 – 10:30 a.m.
|
Information About the Society for Immunotherapy of Cancer Resources
|
10:30 – 11 a.m.
|
Effective Practices for Incorporating Immunotherapy Into Hospital Operations Matthew Zibelman, MD – Fox Chase Cancer Center
|
11 – 11:30 a.m.
|
Coverage and Reimbursement Challenges and Strategies Matthew Zibelman, MD – Fox Chase Cancer Center
|
11:30 – 11:35 a.m.
|
Take-Home Points for Part A
|
11:35 a.m. – noon
|
Lunch
|
Part B: Immune-Related Adverse Event (irAE) Management
|
noon – 12:20 p.m.
|
Mechanisms of Immune-Related Adverse Events Justine V. Cohen, DO – Massachusetts General Hospital
|
12:20 – 12:50 p.m.
|
Nursing Perspective on irAEs: Patient Education, Monitoring and Management Ellen Napier, CRNP – University of Pennsylvania
|
12:50 – 1:20 p.m.
|
Management and Mitigation of irAEs for Immunotherapy Prescribers Kathleen Madden, MSN, FNP-BC, AOCNP, APHN – New York University Cancer Institute
|
1:20 – 1:50 p.m.
|
Identification and Management of Immune-Related Adverse Events in the Emergency Setting Maura Sammon, MD, FAAEM – Temple University School of Medicine
|
1:50 – 1:55 p.m.
|
Posttest Questions by the Society for Immunotherapy of Cancer
|
1:55 – 2 p.m.
|
Take-Home Points for Part B and Closing Remarks
|
The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants
from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.
#InPersonEvent #Pharmacist #Adverse Events
#PrimaryCarePhysician #Introductory
#GenitourinaryCancers #HeadandNeckCancers #LungCancers #2017 #CPE #ImmuneCheckpointInhibitors #Nurse #HematologicMalignancies #ProstateCancer #Patient #Clinician #AlliedHealth #Oncologist #Toxicities
#Cytokines #CME #AdvancesinCancerImmunotherapy(ACI) #CNE #Cancer Immunotherapy Guidelines
#SkinCancers #PatientAdvocate